SCHEMBL16207084

SCHEMBL16207084

C=CC(=O)N1CC[C@@H](Nc2nc(Nc3ccc(N4CCOCC4)c(F)c3)c(C(N)=O)nc2CC)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 9/20 0.70
▸ EML4 Q9HC35 9/20 0.70
▸ ALK Q9UM73 9/20 0.70
▸ RET P07949 8/20 0.70
▸ ROS1 P08922 8/20 0.70
▸ BTK Q06187 3/20 0.56
▸ JAK3 P52333 1/20 0.56
▸ EGFR P00533 3/20 0.54
▸ LCK P06239 1/20 0.54
▸ AXL P30530 4/20 0.53
▸ ETV6 P41212 3/20 0.53
▸ BMPR1B O00238 1/20 0.53
▸ PLK4 O00444 1/20 0.53
▸ CIT O14578 1/20 0.53
▸ AURKA O14965 1/20 0.53
▸ GAK O14976 1/20 0.53
▸ EPHB6 O15197 1/20 0.53
▸ RIPK2 O43353 1/20 0.53
▸ BUB1 O43683 1/20 0.53
▸ SNRNP200 O75643 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16207078 0.92 EML4 (0.65) FLT3EML4ALKRETROS1
SCHEMBL16206848 0.89 ALK (0.68) FLT3EML4ALKRETROS1
SCHEMBL16206853 0.84 EML4 (0.74) FLT3EML4ALKRETROS1
SCHEMBL282851 0.83 EML4 (1.00) FLT3EML4ALKRETROS1
SCHEMBL16207079 0.82 EML4 (0.58) FLT3EML4ALKRETROS1
SCHEMBL22296400 0.81 BTK (0.64) FLT3EML4ALKRETROS1
SCHEMBL16207059 0.81 EML4 (0.72) FLT3EML4ALKRETROS1
SCHEMBL16206833 0.81 EML4 (0.63) FLT3EML4ALKRETROS1
SCHEMBL16207056 0.80 EML4 (0.81) FLT3EML4ALKRETROS1
SCHEMBL16207057 0.80 EML4 (0.81) FLT3EML4ALKRETROS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9085540-B2 Pyrazinecarboxamide compound ASTELLAS PHARMA INC. (JP) 2015-07-21 — — US disclosed
US-9085540-B2 Pyrazinecarboxamide compound ASTELLAS PHARMA INC. (JP) 2015-07-21 — — US disclosed
EP-2805940-A1 PYRAZINE CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2014-11-26 — — EP disclosed
US-20140323463-A1 PYRAZINECARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-10-30 — — US disclosed
US-20140323463-A1 PYRAZINECARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323463-A1 PYRAZINECARBOXAMIDE COMPOUND EGFR, ERBB2, ALK FLT3 24/4885EML4 158/4885ALK 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback